Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIKFYVE | Q9Y2I7 | 4/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.32 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.32 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
| ▸ | PRKX | P51817 | 1/20 | 0.32 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.32 |
| ▸ | TSSK3 | Q96PN8 | 1/20 | 0.32 |
| ▸ | TSSK1B | Q9BXA7 | 1/20 | 0.32 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.32 |
| ▸ | PAK6 | Q9NQU5 | 1/20 | 0.32 |
| ▸ | PAK5 | Q9P286 | 1/20 | 0.32 |
| ▸ | TAOK2 | Q9UL54 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1612864 | 1.00 | PIKFYVE (0.33) | PIKFYVEPTGS2MAP3K14TTBK1PAK4 | |
| SCHEMBL12714624 | 0.84 | MAP3K14 (0.42) | MAP3K14 | |
| SCHEMBL1613202 | 0.73 | MAPT (0.44) | PTGS2ADORA1GABRA5NPC1RAB9A | |
| SCHEMBL1613545 | 0.70 | MAP3K14 (0.48) | MAP3K14 | |
| SCHEMBL1613056 | 0.67 | MAP3K14 (0.46) | MAP3K14 | |
| SCHEMBL1613055 | 0.67 | MAP3K14 (0.46) | MAP3K14 | |
| SCHEMBL1613441 | 0.59 | ALDH1A1 (0.45) | NPC1RAB9A | |
| SCHEMBL1614062 | 0.57 | MAP3K14 (0.56) | PIKFYVEMAP3K14TTBK1 | |
| SCHEMBL1614215 | 0.56 | MAP3K14 (0.57) | MAP3K14PAK4 | |
| SCHEMBL1613149 | 0.56 | MAP3K14 (0.43) | MAP3K14PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2315751-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | Amgen Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009158011-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | AMGEN INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086834-A1 | ALKYNYL ALCOHOLS AS KINASE INHIBITORS | NFKBIA, MAP3K1, MAP3K2 | PIKFYVE 126/4885PTGS2 632/4885MAP3K14 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.